{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:10Z","timestamp":1787020150980,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04599-z","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:05:17Z","timestamp":1768637117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intestinal transcriptomic analysis and prediction of biomarkers associated with mucosal healing following vedolizumab treatment in ulcerative colitis using machine learning"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-5488","authenticated-orcid":false,"given":"Katsuyoshi","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-4281","authenticated-orcid":false,"given":"Shin","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-2413","authenticated-orcid":false,"given":"Aki","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-721X","authenticated-orcid":false,"given":"Hiroaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-8502","authenticated-orcid":false,"given":"Atsuo","family":"Maemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-4840","authenticated-orcid":false,"given":"Takahiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8602-8958","authenticated-orcid":false,"given":"Masaki","family":"Taruishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0322-4507","authenticated-orcid":false,"given":"Kaori","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4321-7774","authenticated-orcid":false,"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"18","key":"4599_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"4599_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26\u201342.","journal-title":"Intest Res"},{"issue":"3","key":"4599_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"4599_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"2","key":"4599_CR5","doi-asserted-by":"publisher","first-page":"e0212989","DOI":"10.1371\/journal.pone.0212989","volume":"14","author":"S Motoya","year":"2019","unstructured":"Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE. 2019;14(2):e0212989.","journal-title":"PLoS ONE"},{"issue":"10","key":"4599_CR6","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.3390\/jcm9103142","volume":"9","author":"BP Vaughn","year":"2020","unstructured":"Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, et al. Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease. J Clin Med. 2020;9(10):3142.","journal-title":"J Clin Med"},{"key":"4599_CR7","doi-asserted-by":"publisher","first-page":"175628481877278","DOI":"10.1177\/1756284818772786","volume":"11","author":"MG Ward","year":"2018","unstructured":"Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therap Adv Gastroenterol. 2018;11:1756284818772786.","journal-title":"Th Adv Gastroenterol"},{"issue":"5","key":"4599_CR8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ecco-jcc\/jjac182","volume":"17","author":"K Uchiyama","year":"2023","unstructured":"Uchiyama K, Takagi T, Mizushima K, Hirai Y, Asaeda K, Sugaya T, et al. Mucosal addressin cell adhesion molecule 1 expression reflects mucosal inflammation and subsequent relapse in patients with ulcerative colitis. J Crohns Colitis. 2023;17(5):786\u201394.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"4599_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","volume":"63","author":"EK Boden","year":"2018","unstructured":"Boden EK, Shows DM, Chiorean MV, Lord JD. Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease. Dig Dis Sci. 2018;63(9):2419\u201329.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"4599_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","volume":"67","author":"I Arijs","year":"2018","unstructured":"Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, et al. Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67(1):43\u201352.","journal-title":"Gut"},{"key":"4599_CR11","doi-asserted-by":"crossref","unstructured":"Haglund S, Soderman J, Almer S. Differences in whole-blood transcriptional profiles in inflammatory bowel disease patients responding to vedolizumab compared with non-responders. Int J Mol Sci. 2023;24(6):5820.","DOI":"10.3390\/ijms24065820"},{"issue":"1","key":"4599_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/s12967-023-04326-w","volume":"21","author":"S Mo","year":"2023","unstructured":"Mo S, Jin B, Tseng Y, Lin L, Lin L, Shen X, et al. A precise molecular subtyping of ulcerative colitis reveals the immune heterogeneity and predicts clinical drug responses. J Transl Med. 2023;21(1):466.","journal-title":"J Transl Med"},{"issue":"1","key":"4599_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41467-018-07841-3","volume":"10","author":"Y Haberman","year":"2019","unstructured":"Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10(1):38.","journal-title":"Nat Commun"},{"issue":"1","key":"4599_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/ibd\/izaa075","volume":"27","author":"CG Fenton","year":"2020","unstructured":"Fenton CG, Taman H, Florholmen J, S\u00f8rbye SW, Paulssen RH. Transcriptional signatures that define ulcerative colitis in remission. Inflamm Bowel Dis. 2020;27(1):94\u2013105.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"4599_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ecco-jcc\/jjz002","volume":"13","author":"END Low","year":"2019","unstructured":"Low END, Mokhtar NM, Wong Z, Raja Ali RA. Colonic mucosal transcriptomic changes in patients with long-duration ulcerative colitis revealed colitis-associated cancer pathways. J Crohns Colitis. 2019;13(6):755\u201363.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"4599_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ibd\/izac230","volume":"29","author":"T Shimoyama","year":"2023","unstructured":"Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S. Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for evaluating clinical and endoscopic disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2023;29(9):1399\u2013408.","journal-title":"Inflamm Bowel Dis"},{"key":"4599_CR17","doi-asserted-by":"publisher","first-page":"175628482097976","DOI":"10.1177\/1756284820979765","volume":"13","author":"RWM Pauwels","year":"2020","unstructured":"Pauwels RWM, van der Woude CJ, Erler NS, de Vries AC. Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therap Adv Gastroenterol. 2020;13:1756284820979765.","journal-title":"Th Adv Gastroenterol"},{"issue":"4","key":"4599_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ibd\/izy304","volume":"25","author":"W Reinisch","year":"2019","unstructured":"Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, et al. Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis: a post hoc analysis of GEMINI 1. Inflamm Bowel Dis. 2019;25(4):803\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"4599_CR19","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/ecco-jcc\/jjaa035","volume":"14","author":"M Coletta","year":"2020","unstructured":"Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, et al. Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases. J Crohns Colitis. 2020;14(9):1190\u2013201.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"4599_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1189\/jlb.3HI0614-303R","volume":"97","author":"EN McNamee","year":"2015","unstructured":"McNamee EN, Masterson JC, Veny M, Collins CB, Jedlicka P, Byrne FR, et al. Chemokine receptor CCR7 regulates the intestinal TH1\/TH17\/Treg balance during Crohn\u2019s-like murine ileitis. J Leukoc Biol. 2015;97(6):1011\u201322.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"4599_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","volume":"65","author":"JB Canavan","year":"2016","unstructured":"Canavan JB, Scott\u00e0 C, Vossenk\u00e4mper A, Goldberg R, Elder MJ, Shoval I, et al. Developing in vitro expanded CD45RA+\u2009regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease. Gut. 2016;65(4):584\u201394.","journal-title":"Gut"},{"issue":"1","key":"4599_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.devcel.2014.05.002","volume":"30","author":"H Sun","year":"2014","unstructured":"Sun H, Liu J, Zheng Y, Pan Y, Zhang K, Chen J. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell. 2014;30(1):61\u201370.","journal-title":"Dev Cell"},{"issue":"5","key":"4599_CR23","doi-asserted-by":"publisher","first-page":"G1257","DOI":"10.1152\/ajpgi.00266.2007","volume":"294","author":"A Miles","year":"2008","unstructured":"Miles A, Liaskou E, Eksteen B, Lalor PF, Adams DH. CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1257\u201367.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"4599_CR24","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1038\/s41467-023-40679-y","volume":"14","author":"P Akbari","year":"2023","unstructured":"Akbari P, Vuckovic D, Stefanucci L, Jiang T, Kundu K, Kreuzhuber R, et al. A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiology. Nat Commun. 2023;14(1):5023.","journal-title":"Nat Commun"},{"key":"4599_CR25","doi-asserted-by":"publisher","first-page":"9621738","DOI":"10.1155\/2021\/9621738","volume":"2021","author":"L Sun","year":"2021","unstructured":"Sun L, Kong R, Li H, Wang D. The role of T follicular helper cells and interleukin-21 in the pathogenesis of inflammatory bowel disease. Gastroenterol Res Pract. 2021;2021:9621738.","journal-title":"Gastroenterol Res Pract"},{"key":"4599_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clim.2018.05.006","volume":"193","author":"JD Lord","year":"2018","unstructured":"Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, et al. Circulating integrin alpha4\/beta7\u2009+\u2009lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018;193:24\u201332.","journal-title":"Clin Immunol"},{"key":"4599_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaut.2018.09.001","volume":"96","author":"R Zhang","year":"2019","unstructured":"Zhang R, Qi CF, Hu Y, Shan Y, Hsieh YP, Xu F, et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. J Autoimmun. 2019;96:113\u201322.","journal-title":"J Autoimmun"},{"issue":"4","key":"4599_CR28","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1053\/j.gastro.2021.06.072","volume":"161","author":"K Lechner","year":"2021","unstructured":"Lechner K, Mott S, Al-Saifi R, Knipfer L, Wirtz S, Atreya R, et al. Targeting of the tec kinase ITK drives resolution of T cell-mediated colitis and emerges as potential therapeutic option in ulcerative colitis. Gastroenterology. 2021;161(4):1270\u201387.e19.","journal-title":"Gastroenterology"},{"key":"4599_CR29","doi-asserted-by":"publisher","first-page":"1343718","DOI":"10.3389\/fimmu.2023.1343718","volume":"14","author":"SW Lee","year":"2023","unstructured":"Lee SW, Park HJ, Van Kaer L, Hong S. Role of CD1d and iNKT cells in regulating intestinal inflammation. Front Immunol. 2023;14:1343718.","journal-title":"Front Immunol"},{"issue":"22","key":"4599_CR30","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1016\/j.febslet.2014.06.042","volume":"588","author":"S Zeissig","year":"2014","unstructured":"Zeissig S, Blumberg RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system. FEBS Lett. 2014;588(22):4188\u201394.","journal-title":"FEBS Lett"},{"issue":"1","key":"4599_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41420-021-00679-7","volume":"7","author":"Z Xie","year":"2021","unstructured":"Xie Z, Zhang M, Zhou G, Lin L, Han J, Wang Y, et al. Emerging roles of the hedgehog signalling pathway in inflammatory bowel disease. Cell Death Discov. 2021;7(1):314.","journal-title":"Cell Death Discov"},{"issue":"47","key":"4599_CR32","doi-asserted-by":"publisher","first-page":"E7545","DOI":"10.1073\/pnas.1616447113","volume":"113","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Rothenberg ME, Seeley ES, Zimdahl B, Kawano S, Lu WJ, et al. Control of inflammation by stromal hedgehog pathway activation restrains colitis. Proc Natl Acad Sci U S A. 2016;113(47):E7545\u2013 E53.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4599_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/187152807783334300","volume":"6","author":"S Sun","year":"2007","unstructured":"Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007;6(4):223\u201335.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"4599_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/abr.abr_24_22","volume":"12","author":"H Asadzadeh-Aghdaei","year":"2023","unstructured":"Asadzadeh-Aghdaei H, Rejali L, Nourian M, Chaleshi V, Zamani N, Baradaran-Ghavami S, et al. Toll-like receptor 7 a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring. Adv Biomed Res. 2023;12:54.","journal-title":"Adv Biomed Res"},{"key":"4599_CR35","doi-asserted-by":"publisher","first-page":"791597","DOI":"10.3389\/fmolb.2021.791597","volume":"8","author":"Y Huang","year":"2021","unstructured":"Huang Y, Jiang Z, Gao X, Luo P, Jiang X. ARMC subfamily: structures, functions, evolutions, interactions, and diseases. Front Mol Biosci. 2021;8:791597.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4599_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12876-022-02475-8","volume":"22","author":"Y-M Ning","year":"2022","unstructured":"Ning Y-M, Lin K, Liu X-P, Ding Y, Jiang X, Zhang Z, et al. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. BMC Gastroenterol. 2022;22(1):392.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"4599_CR37","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1084\/jem.20102683","volume":"208","author":"J VanValkenburgh","year":"2011","unstructured":"VanValkenburgh J, Albu DI, Bapanpally C, Casanova S, Califano D, Jones DM, et al. Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. J Exp Med. 2011;208(10):2069\u201381.","journal-title":"J Exp Med"},{"issue":"12","key":"4599_CR38","doi-asserted-by":"publisher","first-page":"e3001463","DOI":"10.1371\/journal.pbio.3001463","volume":"19","author":"ME Gray","year":"2021","unstructured":"Gray ME, Johnson ZR, Modak D, Tamilselvan E, Tyska MJ, Sotomayor M. Heterophilic and homophilic cadherin interactions in intestinal intermicrovillar links are species dependent. PLoS Biol. 2021;19(12):e3001463.","journal-title":"PLoS Biol"},{"key":"4599_CR39","doi-asserted-by":"publisher","first-page":"701853","DOI":"10.3389\/fcell.2021.701853","volume":"9","author":"AE Paniagua","year":"2021","unstructured":"Paniagua AE, Segurado A, Dol\u00f3n JF, Esteve-Rudd J, Velasco A, Williams DS, et al. Key role for CRB2 in the maintenance of apicobasal polarity in retinal pigment epithelial cells. Front Cell Dev Biol. 2021;9:701853.","journal-title":"Front Cell Dev Biol"},{"key":"4599_CR40","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.48048\/tis.2024.8290","volume":"21","author":"A Wanta","year":"2024","unstructured":"Wanta A, Somsuan K, Dongkaew C, Morchang A, Aluksanasuwan S. Potential oncogenic and immunosuppressive roles of multiple EGF-like domains 6 (MEGF6) in colon cancer: insights from bioinformatic analysis. Trends Sci. 2024;21:8290.","journal-title":"Trends Sci"},{"issue":"12","key":"4599_CR41","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/gutjnl-2018-317571","volume":"68","author":"S van der Post","year":"2019","unstructured":"van der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut. 2019;68(12):2142\u201351.","journal-title":"Gut"},{"issue":"11","key":"4599_CR42","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.3390\/ijms25115817","volume":"25","author":"M Cicala","year":"2024","unstructured":"Cicala M, Gori M, Balestrieri P, Altomare A, Tullio A, Di Cola S, et al. Colonic epithelial permeability to ions is restored after vedolizumab treatment and may predict clinical response in inflammatory bowel disease patients. Int J Mol Sci. 2024;25(11):5817.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4599_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ibd\/izab117","volume":"28","author":"M Gazouli","year":"2022","unstructured":"Gazouli M, Dovrolis N, Bourdakou MM, Gizis M, Kokkotis G, Kolios G, et al. Response to anti-\u03b14\u03b27 Blockade in patients with ulcerative colitis is associated with distinct mucosal gene expression profiles at baseline. Inflamm Bowel Dis. 2022;28(1):87\u201395.","journal-title":"Inflamm Bowel Dis"},{"issue":"23","key":"4599_CR44","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04599-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:02:46Z","timestamp":1770836566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04599-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4599"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04599-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation and Good Clinical Practice guidelines for the conduct of clinical research. The study was approved by the Hokkaido University Certified Review Board (approval no. 020-004), and all patients provided written informed consent before initiation of study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Katsuyoshi Ando reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; grants from Pfizer Inc.; and honoraria for lectures from AbbVie GK, EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Shin Kashima reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Aki Sakatani reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Hiroaki Konishi reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Atsuo Maemoto reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; grants or contracts from AbbVie GK, Eli Lilly Japan K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co. Ltd., Pfizer R&D Japan G.K., and Takeda Pharmaceutical Co. Ltd.; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AbbVie GK, EA Pharma Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Nippon Kayaku Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Takahiro Ito reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; and grants or contracts from AbbVie Inc., Eli Lilly Co. Ltd., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. Masaki Taruishi reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Kaori Ishiguro was an employee of Takeda Pharmaceutical Co. Ltd. at the time this study was conducted. Mikihiro Fujiya reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; and honoraria for speaker bureaus from Takeda Pharmaceutical Co. Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}